Ovid Therapeutics Inc（OVID）股票分析OVIDOvid Therapeutics Inc

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ovid Therapeutics Inc is a good buy right now, trading at $2.16 with a forward P/E of 1.79, suggesting strong future earnings potential. The stock has a projected trajectory indicating a potential increase of 220.74%, supported by positive developments in their drug pipeline and a solid cash position of $165.6 million. However, the main risk is the high insider selling activity, which increased by 668.25% over the last quarter, indicating potential concerns from insiders about the company's future performance.

4 analysts cover OVID: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.17.